Consun Pharmaceutical proposes new share award scheme to incentivize contributors

Consun Pharmaceutical Group Limited announced on November 6, 2025, a proposal to adopt a new Share Award Scheme to recognize and reward participants for their contributions. The board resolved to propose the scheme, which will require approval from shareholders at an extraordinary general meeting (EGM) and, if adopted, will be valid for a term of ten years.

The new scheme is designed to attract suitable personnel and allow participants to acquire equity interests in the company. Awards under the scheme may be satisfied by allotting and issuing new shares directly to the grantee or to a trustee, or by acquiring existing shares. The scheme will be administered by the board, with potential delegation to a committee and appointment of a trustee.

The total number of shares that may be issued under the new scheme, combined with the 2024 Share Option Scheme and any other share schemes, shall not exceed 84,281,191 shares (9.94% of issued shares as of the announcement date). This excludes outstanding options from the expired 2013 Share Option Scheme and treasury shares. The 2024 Share Option Scheme was adopted on May 31, 2024, with a mandate limit of 84,281,191 shares, though no options have been granted under it to date.